Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004030339 | SCV001172836 | uncertain significance | not specified | 2022-12-23 | criteria provided, single submitter | clinical testing | The p.K546R variant (also known as c.1637A>G), located in coding exon 10 of the GALNT12 gene, results from an A to G substitution at nucleotide position 1637. The lysine at codon 546 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001862787 | SCV002263347 | uncertain significance | not provided | 2023-02-04 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 819655). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GALNT12 protein function. This variant has not been reported in the literature in individuals affected with GALNT12-related conditions. This variant is present in population databases (rs374166991, gnomAD 0.01%). This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 546 of the GALNT12 protein (p.Lys546Arg). |
Baylor Genetics | RCV004569899 | SCV005058820 | uncertain significance | Colorectal cancer, susceptibility to, 1 | 2024-02-01 | criteria provided, single submitter | clinical testing |